EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Advances in the development of personalized neoantigen therapies

Spencer E Mirabile-Brightman iD, Lisa H Butterfield iD

Journal of Experimental Medicine · 02.02.2026 · 223 (2)

DOI: 10.1084/jem.20241234 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Experimental Medicine, online erschienen am 09.12.2025. Verfasst von Spencer E Mirabile-Brightman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cancer Immunotherapy, La Jolla Institute for Immunology , La Jolla, CA, USA. Hauptthemen laut MEDLINE: Precision Medicine, Antigens, Neoplasm, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 123 Literaturangaben. Gefördert von: Briger Foundation for Oncology Research, Troper Wojcicki Philanthropies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ability to specifically engage tumor-reactive T cells for therapeutic benefit is the ultimate goal of cancer immunotherapy. Whereas currently approved immunotherapies leverage and modulate existing endogenous T cells in an antigen non-specific manner, cancer vaccines and neoantigen therapeutics promise the ability to selectively amplify T cells specific for targeted antigens. Advances in the identification of tumor-specific antigens coupled with a greater understanding of T cell biology and immunization platforms have culminated in recent trials where signs of clinical efficacy have been observed, particularly in randomized adjuvant clinical settings. In this review, we discuss the identification of tumor-specific antigens for cancer therapy, the benefits of including antigens recognized by CD4+ T cells, clinical data investigating novel immunization platforms, and emerging clinical settings where promotion of tumor-specific immunity may be optimal.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineAntigens, NeoplasmNeoplasmsImmunotherapyCancer VaccinesHumansAnimalsCD4-Positive T-Lymphocytes

Substanzen

Antigens, NeoplasmCancer Vaccines

Autor:innen und Institutionen

  • Center for Cancer Immunotherapy, La Jolla Institute for Immunology , La Jolla, CA, USA.
  • Merck Research Laboratories , South San Francisco, CA, USA.

ORCID-Profile: Spencer E Mirabile-Brightman, Lisa H Butterfield

Förderung

  • Briger Foundation for Oncology Research
  • Troper Wojcicki Philanthropies

Zitieren

APA

Mirabile-Brightman, S. E., & Butterfield, L. H. (2026). Advances in the development of personalized neoantigen therapies. Journal of Experimental Medicine, 223(2). https://doi.org/10.1084/jem.20241234

Vancouver

Mirabile-Brightman SE, Butterfield LH. Advances in the development of personalized neoantigen therapies. Journal of Experimental Medicine. 2026;223(2). doi:10.1084/jem.20241234

BibTeX
@article{MirabileBrightman2026,
  author = {Mirabile-Brightman, Spencer E and Butterfield, Lisa H},
  title = {Advances in the development of personalized neoantigen therapies},
  journal = {Journal of Experimental Medicine},
  year = {2026},
  volume = {223},
  number = {2},
  doi = {10.1084/jem.20241234}
}
Kostenlos starten →